Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.54 |
| ▸ | CA2 | P00918 | 13/20 | 0.54 |
| ▸ | MMP1 | P03956 | 13/20 | 0.54 |
| ▸ | MMP2 | P08253 | 13/20 | 0.54 |
| ▸ | MMP9 | P14780 | 13/20 | 0.54 |
| ▸ | MMP8 | P22894 | 13/20 | 0.54 |
| ▸ | MMP13 | P45452 | 13/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | PKLR | P30613 | 2/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15116336 | 0.77 | PKM (0.49) | CA1CA2PKMPKLRSLC40A1 | |
| SCHEMBL420075 | 0.77 | PKM (0.49) | PKMPKLRSLC40A1 | |
| SCHEMBL1767641 | 0.76 | CA1 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL9678567 | 0.75 | PKM (0.44) | CA1CA2MMP2PKMPKLR | |
| SCHEMBL7595736 | 0.74 | SLC40A1 (0.61) | CA1CA2PKMSLC40A1 | |
| SCHEMBL424801 | 0.74 | PKM (0.46) | PKMPKLRSLC40A1HPGD | |
| SCHEMBL424802 | 0.74 | PKM (0.46) | PKMPKLRSLC40A1 | |
| SCHEMBL795356 | 0.73 | PKM (0.50) | PKMPKLRSLC40A1CES2CES1 | |
| SCHEMBL1767985 | 0.73 | ATM (0.50) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL15621569 | 0.72 | KDM4E (0.50) | PKMPKLRSLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053915-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2021-02-25 | — | — | US | disclosed |
| US-10829445-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3124471-B1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | UNIV JOHNS HOPKINS (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20190144380-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| US-10179765-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-9969684-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969684-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170305847-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2017-10-26 | — | — | US | disclosed |
| US-20170305847-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2017-10-26 | — | — | US | disclosed |
| US-9725410-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-08 | — | — | US | disclosed |
| US-20110306614-A1 | N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-12-15 | — | — | US | disclosed |
| US-8030356-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030356-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011063339-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063400-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | NATIONAL SCIENCE FOUNDATION | 2007-12-27 | — | — | US | disclosed |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | NATIONAL SCIENCE FOUNDATION | 2007-12-27 | — | — | US | disclosed |
| WO-2007109175-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306614-A1 | N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors | TNNI3, TNNC1, NME4 | CA1 2599/4885CA2 1456/4885MMP1 2327/4885 |
| US-20210053915-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, TNNT2 | CA1 2645/4885CA2 1468/4885MMP1 2368/4885 |
| US-10829445-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | TNNI3, TNNC1, TNNT2 | CA1 2645/4885CA2 1468/4885MMP1 2368/4885 |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | NOS2, NOS3, NOS1 | CA1 3870/4885CA2 747/4885MMP1 1165/4885 |
| US-20190144380-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, TNNT2 | CA1 2645/4885CA2 1468/4885MMP1 2368/4885 |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | TNNI3, TNNC1, NME4 | CA1 2599/4885CA2 1456/4885MMP1 2327/4885 |
| US-10179765-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | TNNI3, TNNC1, TNNT2 | CA1 2645/4885CA2 1468/4885MMP1 2368/4885 |
| US-20170305847-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | CA1 2599/4885CA2 1456/4885MMP1 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.